礼来公司修订细胞周期特异性抗肿瘤药GEMZAR的说明书

2017-11-29 朱明静 国际药政通

注射用盐酸吉西他滨(GEMCITABINE HYDROCHLORIDE for Injection),商品名健择(GEMZAR)是美国礼来公司研发的产品,至今共修订该药品说明书11次。礼来公司根据《联邦食品药品和化妆品法案》第505(b)条规定提交补充新药申请(sNDA),提出修改规格为200mg (以C9H11F2N3O4计)、1g (以C9H11F2N3O4计)的注射用盐酸吉西他滨说明书,并于


注射用盐酸吉西他滨(GEMCITABINE HYDROCHLORIDE for Injection),商品名健择(GEMZAR)是美国礼来公司研发的产品,至今共修订该药品说明书11次。礼来公司根据《联邦食品药品和化妆品法案》第505(b)条规定提交补充新药申请(sNDA),提出修改规格为200mg (以C9H11F2N3O4计)、1g (以C9H11F2N3O4计)的注射用盐酸吉西他滨说明书,并于2017年9月13日发布新版说明书,修订补充申请-79(SUPPL-79)说明书的内容。

1. GEMZAR说明书修改内容

8【特殊人群用药】

第8.4项“儿童用药”部分,将儿科患者的最大耐受剂量从“10 mg/m²/min,静脉注射360min,每周3次,然后休息一周”修订为“10 mg/m²/min,静脉注射360min,每周1次,连续3周,然后休息一周”;增加“M1或M2骨髓增生异常综合征患者在治疗的第28天时,若未出现严重的毒性反应,可再接受一次最长不超过4周的治疗”。

2. GEMZAR简介

GEMZAR,化学名称(+)2'-脱氧-2'2'-二氟胞嘧啶盐酸盐,是一种新型人工合成的嘧啶核苷酸类似物,主要通过抑制肿瘤细胞 DNA 合成, 将细胞阻断在 G1 期,最终导致肿瘤细胞凋亡,而发挥其细胞毒作用,属细胞周期特异性抗肿瘤药[1] 。研究表明,GEMZAR是目前疗效较好毒副作用较少的新型抗肿瘤药,肺泡巨噬细胞(AM)是肺组织中的主要免疫细胞,肺泡巨噬细胞受到活化 (LPS、IL-2、GSP) 等刺激以后,能分泌多种细胞因子,如TNF-α、NO、白介素等,在肿瘤免疫中发挥重要作用[2~4]。

3. GEMZAR适用症

(1)卵巢癌:GEMZAR与卡铂联合用于治疗完成铂类治疗后6个月内复发的晚期卵巢癌患者。

(2)乳腺癌:吉西他滨与紫杉醇联合,适用于治疗经辅助化疗后复发,不能切除的、局部复发或转移性乳腺癌。除非临床上有禁忌,否则既往化疗中应使用过蒽环类抗生素

(3)非小细胞肺癌:与顺铂联合用于一线治疗无法手术的晚期(IIIA期或IIIB期)或转移性(IV期)非小细胞肺癌患者。

(4)胰腺癌:用于局部晚期(不可切除的II期或III期)或转移性(IV期)胰腺癌。适用于以前用5-FU治疗的患者。

4. GEMZAR在中国的上市情况

目前,礼来公司生产的GEMZAR已在中国上市,剂型分别为200mg(以C9H11F2N3O4计)、1g(以C9H11F2N3O4计) 。

参考文献:

[1]李龙芸,胡晶晶,张 力.健择治疗非小细胞肺癌研究现状[J].中国肺癌杂志,2000,3(4):151- 154.

[2]刘艺萍,周柔丽.巨噬细胞的抗肿瘤效应[J].国外医学免疫学分册, 1998,21 (4)207- 210.

[3]胡成平,李固本,吴鄂生,等.肺癌患者肺泡巨噬细胞一氧化氮活性研究[J].湖南医科大学学报,1998,23(2):157- 160.

[4]信  涛,徐玉清,姜秋颖,等.TNF2 和 Bcl- 2 在大肠癌中的表达及意义[J].中国现代医学杂志,2003,13(13):87- 89.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036947, encodeId=25ac203694e2f, content=<a href='/topic/show?id=01f6e92398' target=_blank style='color:#2F92EE;'>#GEMZAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7923, encryptionId=01f6e92398, topicName=GEMZAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Apr 29 03:25:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899175, encodeId=ca1c18991e57c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 11 06:25:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287508, encodeId=07dd128e508ba, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507156, encodeId=d5a3150e1563c, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537698, encodeId=3e08153e6980e, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593686, encodeId=1b2915936863a, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265353, encodeId=9ebb265353ce, content=学习了!受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Nov 29 14:06:06 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
    2018-04-29 lfyang
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036947, encodeId=25ac203694e2f, content=<a href='/topic/show?id=01f6e92398' target=_blank style='color:#2F92EE;'>#GEMZAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7923, encryptionId=01f6e92398, topicName=GEMZAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Apr 29 03:25:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899175, encodeId=ca1c18991e57c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 11 06:25:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287508, encodeId=07dd128e508ba, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507156, encodeId=d5a3150e1563c, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537698, encodeId=3e08153e6980e, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593686, encodeId=1b2915936863a, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265353, encodeId=9ebb265353ce, content=学习了!受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Nov 29 14:06:06 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036947, encodeId=25ac203694e2f, content=<a href='/topic/show?id=01f6e92398' target=_blank style='color:#2F92EE;'>#GEMZAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7923, encryptionId=01f6e92398, topicName=GEMZAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Apr 29 03:25:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899175, encodeId=ca1c18991e57c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 11 06:25:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287508, encodeId=07dd128e508ba, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507156, encodeId=d5a3150e1563c, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537698, encodeId=3e08153e6980e, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593686, encodeId=1b2915936863a, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265353, encodeId=9ebb265353ce, content=学习了!受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Nov 29 14:06:06 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036947, encodeId=25ac203694e2f, content=<a href='/topic/show?id=01f6e92398' target=_blank style='color:#2F92EE;'>#GEMZAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7923, encryptionId=01f6e92398, topicName=GEMZAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Apr 29 03:25:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899175, encodeId=ca1c18991e57c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 11 06:25:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287508, encodeId=07dd128e508ba, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507156, encodeId=d5a3150e1563c, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537698, encodeId=3e08153e6980e, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593686, encodeId=1b2915936863a, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265353, encodeId=9ebb265353ce, content=学习了!受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Nov 29 14:06:06 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2036947, encodeId=25ac203694e2f, content=<a href='/topic/show?id=01f6e92398' target=_blank style='color:#2F92EE;'>#GEMZAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7923, encryptionId=01f6e92398, topicName=GEMZAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Apr 29 03:25:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899175, encodeId=ca1c18991e57c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 11 06:25:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287508, encodeId=07dd128e508ba, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507156, encodeId=d5a3150e1563c, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537698, encodeId=3e08153e6980e, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593686, encodeId=1b2915936863a, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265353, encodeId=9ebb265353ce, content=学习了!受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Nov 29 14:06:06 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2036947, encodeId=25ac203694e2f, content=<a href='/topic/show?id=01f6e92398' target=_blank style='color:#2F92EE;'>#GEMZAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7923, encryptionId=01f6e92398, topicName=GEMZAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Apr 29 03:25:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899175, encodeId=ca1c18991e57c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 11 06:25:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287508, encodeId=07dd128e508ba, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507156, encodeId=d5a3150e1563c, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537698, encodeId=3e08153e6980e, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593686, encodeId=1b2915936863a, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265353, encodeId=9ebb265353ce, content=学习了!受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Nov 29 14:06:06 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2036947, encodeId=25ac203694e2f, content=<a href='/topic/show?id=01f6e92398' target=_blank style='color:#2F92EE;'>#GEMZAR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7923, encryptionId=01f6e92398, topicName=GEMZAR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Sun Apr 29 03:25:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899175, encodeId=ca1c18991e57c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Fri May 11 06:25:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287508, encodeId=07dd128e508ba, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507156, encodeId=d5a3150e1563c, content=<a href='/topic/show?id=18849189139' target=_blank style='color:#2F92EE;'>#说明书#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91891, encryptionId=18849189139, topicName=说明书)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3da79876963, createdName=yangpeizhi, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537698, encodeId=3e08153e6980e, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593686, encodeId=1b2915936863a, content=<a href='/topic/show?id=ff895565586' target=_blank style='color:#2F92EE;'>#抗肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55655, encryptionId=ff895565586, topicName=抗肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5e18156549, createdName=zhu_jun9843, createdTime=Fri Dec 01 01:25:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265353, encodeId=9ebb265353ce, content=学习了!受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Nov 29 14:06:06 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
    2017-11-29 131****1460

    学习了!受益匪浅

    0

相关资讯

2017,这10大重磅药物专利悬了!(礼来、吉利德、辉瑞、诺华……)

专利对于药物而言,相当于生命周期的结点。药物专利一旦到期,企业依靠专利保护获得的销售额和利润会一落千丈,很多昔日业绩显赫的明星药物因为专利危机而惨淡退场。2017年,又有哪些重磅药物将遭遇专利悬崖呢?近日,FiercePharma推出“Top 10 U.S. patent losses of 2017”,列举了10款即将在2017年面临专利过期的药物,它们分别来自于礼来、辉瑞、吉利德、诺华……

喜讯!欧盟CHMP支持批准礼来单抗药olaratumab联合阿霉素治疗晚期软组织肉瘤

美国医药巨头礼来(Eli Lilly)抗癌管线近日在欧盟监管方面传来喜讯,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)已发布积极意见,支持有条件批准单抗药物olaratumab联合阿霉素(doxorubicin)用于不适合放疗或手术根治的晚期软组织肉瘤患者的治疗。这也将是礼来在欧盟方面的首个有条件批准。作为有条件批准的一部分,礼来后续需要提交正在开展的olaratumab治疗晚期软组织肉

ADA 2016:勃林格-礼来降糖药Tradjenta(利拉利汀)显著降低伴有肾损伤风险的2型糖尿病患者血糖水平

勃林格殷格翰——礼来糖尿病联盟近日在美国新奥尔良举行的2016年第76届美国糖尿病协会(ADA)科学会议(2016年06月10日-14日)上公布了糖尿病药物Tradjenta(linagliptin,利拉利汀)一项新的研究(MARLINA-T2D)数据。该研究结果显示,Tradjenta能够有效降低伴有肾损伤风险的2型糖尿病患者的血糖水平,该药的肾脏安全性与其他临床研究中一致。 据估计,有多达一

重磅!勃林格-礼来降糖药Jardiance在确诊心血管疾病的2型糖尿病患者中显著延缓肾病进展风险

勃林格殷格翰-礼来糖尿病联盟近日在美国新奥尔良举行的2016年第76届美国糖尿病协会(ADA)科学会议(2016年06月10日-14日)上公布了糖尿病药物Jardiance(empagliflozin,恩格列净)里程碑意义的临床研究(EMPA-REG OUTCOME)新的分析数据。数据显示,在确诊心血管(CV)疾病的2型糖尿病成人患者中,与安慰剂+标准护理(包括降糖药和CV药物)相比,Jard

礼来携手勃林格殷格翰研发乳腺癌组合疗法

制药巨头礼来和勃林格殷格翰近日达成一项研究合作,二者将共同研发乳腺癌联合用药。此次合作的焦点是研究勃林格殷格翰胰岛素样生长因子-1/2(IGF-1/2)配体的中和抗体BI 836845和礼来CDK4/CDK6抑制剂abemaciclib联合疗法在乳腺癌中的安全性和有效性。 Ib期安全性试验将于今年开展,受试者为确诊HR+/HER2-的晚期乳腺癌患者。如果进展顺利,双方继续开展中期临床试验,以及在

**“搞科研”的礼来竟然裁撤了研发中心! 预计3500人将被裁员

礼来将关闭位于上海张江的早期临床研究实验室,将在华研发活动的重心转到更多通过本土协作和合作伙伴关系来推动早期和临床领域研究上来。